TOPICS
Content Distribution for Biotech & Pharma
DIRECT ANSWER
Content distribution is the process of amplifying and delivering published content to target audiences through owned, earned, and paid channels. It determines whether content reaches the people it was designed for, making it at least as important as content creation. A strong piece of content with poor distribution generates less business impact than mediocre content placed precisely in front of the right audience at the right moment. For Biotech & Pharma companies, this matters because Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch.
What content distribution means for Biotech & Pharma
The MLR bottleneck is the defining pain. Position AI-CMO as a pre-MLR content acceleration layer — draft variations auto-generated with reference tagging to approved label language, so reviewers approve faster. Integration with Veeva Vault PromoMats is table stakes for enterprise deals. Secondary angle: omnichannel orchestration for HCP journeys that synchronize rep calls, emails, and event invites without manual coordination.
For Biotech & Pharma teams the relevant marketing pains are: Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch; HCP segmentation is done manually in Excel — field reps don't have actionable, data-driven targeting for their territories; Congress season (ASCO, ADA, ACC) creates content demand spikes that small medical affairs teams cannot absorb; Patient support programs are marketed reactively rather than through proactive lifecycle journeys; KOL engagement tracking is scattered across MSL notes, CRM fields, and email threads with no unified view; Brand teams in different therapeutic areas duplicate research and creative work with no shared asset library. FDA 21 CFR Part 202 (prescription drug advertising); FDA guidance on social media and internet promotion; OPDP fair balance requirements; EFPIA Code (EU); PhRMA Code on interactions with HCPs; HIPAA for patient data; MLR approval documentation must be retained; off-label promotion prohibition is absolute
Owned, Earned, and Paid Distribution
Owned distribution channels — your email list, website, organic social, and in-app notifications — are the foundation. They are free to use after the infrastructure is built and scale with audience size. Earned distribution — press coverage, organic shares, backlinks, podcast appearances — extends reach beyond your owned channels without incremental spend but requires relationship investment and compelling content worth amplifying.
Paid distribution — sponsored social posts, native advertising, content syndication networks, newsletter sponsorships — accelerates reach for content that has demonstrated organic performance or that targets a very specific audience hard to reach through owned and earned channels alone. Paid amplification of already-proven content is more efficient than using paid to launch unproven content.
Running content distribution for Biotech & Pharma with CoMo
CoMo's agents apply content distribution across HCP email, med-ed portals, LinkedIn, congresses/events, speaker programs, rep-triggered digital, patient advocacy partnerships for Biotech & Pharma companies — tuned to VP Commercial Marketing at mid-size pharma; Director of Marketing Excellence at specialty biotech; Head of Omnichannel at large pharma and run under your approval, alongside every other marketing function.
FAQ
Content Distribution for Biotech & Pharma — common questions
How do we prioritize which distribution channels to invest in?
Start where your target audience is already concentrated and where you can realistically produce content at competitive quality. Score channels on: audience size in your ICP, cost per reached contact, time to see results, and your team's current capability. Start with one or two channels, build competency, then expand.
How does content distribution differ for Biotech & Pharma companies?
The fundamentals are the same, but Biotech & Pharma marketing carries specific constraints — Medical, Legal, Regulatory (MLR) review queues create 4–8 week delays that make campaigns stale before they launch and FDA 21 CFR Part 202 (prescription drug advertising); FDA guidance on social media and internet promotion; OPDP fair balance requirements; EFPIA Code (EU); PhRMA Code on interactions with HCPs; HIPAA for patient data; MLR approval documentation must be retained; off-label promotion prohibition is absolute. CoMo adapts execution to that context automatically.
BUILT BY COMO'S AGENTS
This page was written by CoMo — the autonomous CMO.
CoMo runs every channel of your marketing on your live data. See it work on your brand.